. 2014 Nov 5;9:1879–1893. doi: 10.2147/CIA.S70307

Table 3.

Studies reporting mean (SD) percentage change in or mean (SD) concentrations for biochemical markers of bone turnover after 52 weeks of RLX treatment

Authors	Therapy	Serum BAP (% or U/L)	CTx (% or μg/L)	NTx (% or nmol BCE/L)
Randomized controlled trials
Morii et al³⁵,^a,^b	RLX RLX (120 mg/day)	NR (NR)^* NR (NR)^*	NR (NR)^*,^c NR (NR)^*,^c	NR (NR)^*,^c NR (NR)^*,^c
Iwamoto et al³¹	ALN RLX	−18 (NR)^*,^d −10 (NR)^*,^d	NM NM	−45 (NR)^*,^c,^e −35 (NR)^*,^c,^e
Majima et al³³	RLX RLX + ALF	−20 (37)^* −20 (29)^**	NM NM	−29 (20)^,^f −25 (17)^,^f
Gorai et al²⁹,^g	RLX ALF RLX + ALF	−22 (NR) NR (NR) −37 (NR)	−37 (NR)^c NR (NR)^c −42 (NR)^c	NR (NR)^c NR (NR)^c −35 (NR)^c
Gorai et al³²,^a	RLX ALF RLX + ALF	NR (NR)^* NR (NR) NR (NR)^***	NR (NR)^*,^c NR (NR) NR (NR)^*,^c	NR (NR)^*,^c NR (NR) NR (NR)^*,^c
Ando et al³⁰,^g,^h	All RLX am RLX pm	−32 (−43 to −22)ⁱ −26 (−39 to −13)ⁱ −38 (−55 to −21)ⁱ	NM NM NM	NM NM NM
Observational studies
Majima et al³⁶	RLX	33 (16), 24 (9)^**	NM	19 (6), 14 (3)^**,^f
Majima et al³⁷	RLX	33 (17), 23 (9)^**	NM	19 (5), 14 (3)^**,^f
Majima et al³⁸	RLX	33 (16), 24 (9)^**	NM	20 (5), 14 (3)^**,^f
Iikuni et al⁴⁰,^a,^j	RLX	NR (NR)^***	NM	NR (NR)^***,^c
Takada et al³⁹,^g	RLX	NM	NM	−13.5 (NR)^f,^k

Notes:

P<0.05,

^**

P<0.01, and

^***

P<0.001 indicate significant differences from baseline

study presented data of biochemical markers of bone turnover in figures, but did not report specific values in the figure or results text

osteocalcin levels were also measured in this study; statistically significant (P<0.001) reductions from weeks 0 to 52 were reported

urinary levels tested

serum alkaline phosphatase levels were measured

mean (SD) percentage change for NTx is from week 0 to week 12

serum levels tested

authors did not specify the value of statistical significance for bone biochemical marker reductions

tartrate-resistant acid phosphatase levels were also measured in this study; the mean (95% CI) percentage change from week 0 to 52 was −27 (−33 to −21) mU/dL for all postmenopausal women, −31 (−40 to −22) mU/dL for the RLX am group, and −23 (−32 to −14) mU/dL for the RLX pm group

ⁱ

values are means (95% CI)

urinary deoxypyridinoline levels were also measured in this study; statistically significant (P<0.001) reductions from week 0 to 52 were reported

values are medians; median percentage change for NTx is from week 0 to week 26.

Abbreviations: ALF, alfacalcidol; ALN, alendronate; BAP, bone-specific alkaline phosphatase; BCE, bone collagen equivalents; CTx, type 1 collagen C-telopeptide; NM, not measured; NR, not reported; NTx, type 1 collagen N-telopeptide; RLX, raloxifene 60 mg/day; SD, standard deviation; CI, confidence interval.